Radiopharmaceuticals for Bone Malignancy Therapy

Journal of Nuclear Medicine Technology

Harold L. Atkins¹  Suresh C. Srivastava¹ 

[1] Medical Department, Brookhaven National Laboratory, Upton, New York Medical Department, Brookhaven National Laboratory, Upton, New York Medical Department, Brookhaven National Laboratory, Upton, New York

关键词: cancer;    radionuclide therapy of bone malignancies;    palliation from metastases to bone;    strontium-89;    phosphorus-32;    tin-117m;    rhenium-186;    samarium-153;   

DOI  :  

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Objective: This continuing education article reviews radionuclide bone therapy agents that are available commercially and introduces agents that are being evaluated for future use. Currently these agents are used to provide pain palliation from metastases to bone. Future applications may include adjuvant therapy to surgery or external beam treatment. After reading this paper, the reader should be able to: (a) describe the desirable characteristics of radionuclide bone therapy agents; (b) compare and contrast radiopharmaceuticals available for bone therapy; and (c) state the clinical applications of radionuclide bone therapy agents.

【 授权许可】

Unknown